Catheter Precision, INC 8-K filings

Catheter Precision's stockholders approved several key proposals at a special meeting, including increasing authorized shares and approving a new equity incentive plan.

Catheter Precision has appointed Philip Anderson as its new Chief Financial Officer, effective January 6, 2025, replacing interim CFO Margrit Thomassen.

Catheter Precision announced its third quarter financial results and provided an operational update, noting progress in commercial activities, clinical studies, and regulatory approvals.

Catheter Precision has repriced its outstanding warrants, potentially raising $3.7 million through immediate exercises and issuing new warrants.

Catheter Precision has waived a beneficial ownership limitation, allowing the Jenkins Family Charitable Institute to fully exercise its pre-funded warrants and increase its stake in the company.

Catheter Precision has repriced existing warrants and secured approximately $4.9 million in gross proceeds through immediate exercises and prior exercises.

Catheter Precision closed a $3.6 million underwritten public offering, including the exercise of the underwriters' overallotment option, to fund its innovative medical device development.

Catheter Precision has amended its short-term promissory notes, extending the maturity date to January 31, 2026, and increasing the interest rate to 12% from August 31, 2024.

Catheter Precision announced its Q2 2024 financial results, including the first commercial sales of its LockeT device and progress in hospital evaluations for both LockeT and VIVO products.

Catheter Precision, Inc. has obtained a $500,000 short-term loan from the Jenkins Family Charitable Institute, adding to previous loans from related parties.

Catheter Precision has converted all outstanding Series A Preferred Stock into 25,000 shares of common stock, eliminating the preferred stock class.

Catheter Precision, Inc. received a $100,000 short-term loan from its CEO, David A. Jenkins, with an 8% interest rate, due August 30, 2024.

Catheter Precision has enacted a 1-for-10 reverse stock split and reduced its authorized common stock from 300 million to 30 million shares, effective July 15, 2024.

Catheter Precision stockholders approved several key proposals at their annual meeting, including an increase in shares for the equity incentive plan and a potential reverse stock split.

Catheter Precision announced a 15% quarter-over-quarter revenue increase, driven by initial sales of its LockeT device, and a 1-for-10 reverse stock split effective July 15, 2024.

Catheter Precision, Inc. has obtained a $250,000 short-term loan from its Executive Chair and CEO, David A. Jenkins, to be repaid from potential proceeds of a future securities sale.

Catheter Precision, Inc. has obtained a $150,000 short-term loan from its Executive Chair and CEO, David A. Jenkins, with repayment expected from proceeds of a future securities sale.

Catheter Precision has entered into a royalty agreement with a co-inventor of their LockeT device and secured a $500,000 short-term loan from its Executive Chair and CEO.

John P. Francis will not seek reelection to the Board of Directors of Catheter Precision, Inc. at the upcoming 2024 Annual Meeting of Stockholders.

Catheter Precision announced its Q1 2024 financial results, along with operational updates on its LockeT and VIVO products, including progress on regulatory approvals and clinical data.

Catheter Precision filed a revised consent from its independent accounting firm to correct references to registration statements in its recent annual report.

Catheter Precision, Inc. announced its Q4 and full-year 2023 financial results, highlighting significant revenue growth and progress in clinical trials and patent filings.

Catheter Precision issued 546,776 shares of common stock following the conversion of Series A Convertible Preferred Stock on January 23, 2024.

Catheter Precision announced unaudited preliminary fourth quarter and full year 2023 results, including revenue of $129,000 for the quarter and $442,000 for the year, alongside key product and market developments.